FindTrial
Sign In

Platinum Compound

DRUG2 trials

Sponsors

National Cancer Institute (NCI), SWOG Cancer Research Network

Conditions

Autoimmune DiseaseCrohn DiseaseDermatomyositisExtensive Stage Lung Small Cell CarcinomaHematopoietic and Lymphoid Cell NeoplasmInflammatory Bowel DiseaseLung Small Cell Carcinoma, A SubtypeLung Small Cell Carcinoma, I Subtype

Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingNCT03816345
National Cancer Institute (NCI)Autoimmune Disease, Crohn Disease, Dermatomyositis +11
Start: 2019-07-16End: 2028-03-30Target: 300Updated: 2026-05-13

Phase 2

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
RecruitingNCT06769126
SWOG Cancer Research NetworkExtensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype +2
Start: 2025-11-06End: 2029-12-31Target: 900Updated: 2026-03-30

Related Papers

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
2021-06-2334 citations
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Journal of Clinical Oncology2021-05-2029 citations
Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)
Cancer Research2020-08-15
A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Journal of Clinical Oncology2020-05-206 citations